Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
AssigneesUniversity of Massachusetts, Beth Israel Deaconess Medical Center, Inc.
InventorsAnastasia Khvorova, Melissa Moore, Anton A. Turanov, Ananth Karumanchi
Life of this patent
Estimating the term…
Abstract
This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
Claims34
A compound that binds to an intronic region of an mRNA encoding an sFLT1 protein, wherein the compound selectively inhibits expression of the sFLT1 protein in a cell or organism.
(canceled)
(canceled)
(canceled)
9-11. (canceled)
(canceled)
(canceled)
16-21. (canceled)
A therapeutic compound that binds to an intronic region of an mRNA encoding an sFLT1 protein, wherein the therapeutic compound selectively reduces expression of the sFLT1 protein, and wherein the therapeutic compound reduces one or more symptoms of preeclampsia (PE), postpartum PE, eclampsia or Hemolysis/Elevated Liver enzymes/Low Platelet count (HELLP) syndrome when administered to a subject in need thereof.
(canceled)
(canceled)
27-31. (canceled)
33-35. (canceled)
A pharmaceutical composition comprising:
- a first dsRNA comprising a first sense strand and a first antisense strand, wherein the first antisense strand comprises a region of complementarity which is substantially complementary to SEQ ID NO:1, and wherein the first antisense strand selectively targets one or both of an intronic region of sFLT-i13 short and an intronic region of sFLT-i13 long;
- a second dsRNA comprising a second sense strand and a second antisense strand, wherein the second antisense strand comprises a region of complementarity which is substantially complementary to SEQ ID NO:2, and wherein the second antisense strand selectively targets an intronic region of sFLT-i15a;
- and
- a pharmaceutically acceptable carrier.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.